Project Grant R00MH129616
- The National Institute of Mental Health (NIMH) awarded a $156,500 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to Emory University to identify patients with true treatment failure for major depressive disorder (MDD) who may benefit from earlier referral to alternative treatments like transcranial magnetic stimulation, ketamine, and vagus nerve stimulation. The project aims to use trajectory classification methods to empirically separate partial response from true...
- This $576,337 National Institute of Mental Health project grant funds research at Stanford University to evaluate a biomarker-guided intervention approach for anhedonia in treatment-resistant depression. The grant supports a clinical trial targeting D3 receptor agonism with pramipexole to determine its effects on ventral striatum brain activation as measured by functional neuroimaging. The study aims to enroll treatment-resistant depression patients with prominent anhedonia to evaluate whether...
- This federal Project Grant award, titled "MAINTENANCE RTMS FOR DEPRESSION (MAITR-DE)", is funded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242). The $968,769 award will support a multi-site study to investigate the efficacy of maintenance repetitive transcranial magnetic stimulation (rTMS) in sustaining treatment response for individuals with treatment-resistant depression. The study will be conducted by the University of...
- Federal Project Grant Award Summary The National Institute of Mental Health (NIMH) awarded a $433,125 Project Grant to the University of California, Los Angeles on June 15, 2026, under the Mental Health Research Grants program (CFDA 93.242). This two-year research initiative, completing June 14, 2028, investigates cell-free DNA (cfDNA) as a biomarker for electroconvulsive therapy (ECT) efficacy in treating treatment-resistant depression (TRD). The research leverages UCLA's participation in an...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded The Leland Stanford Junior University a $1.07 million Project Grant under the Mental Health Research Grants program (CFDA 93.242) for a two-year effort running from April 1, 2026, through January 31, 2028. This research initiative develops and validates a personalized neuromodulation protocol using early transcranial magnetic stimulation-electroencephalography (TMS-EEG) potentials as biomarkers to optimize...
- Federal Grant Award Summary The Laureate Institute for Brain Research, Inc. received a $514,178 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), effective July 1, 2025, through April 30, 2030. The award funds a five-year research initiative investigating the mechanistic relationships between brain circuits and negative valence system behaviors in treatment-resistant depression (TRD) using low-intensity...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded Washington University a Project Grant totaling $284,333 under the Mental Health Research Grants program (CFDA 93.242) on August 4, 2025, for research on mechanism-based dose titration strategies to modify brain electrophysiology during antidepressant therapy for treatment-resistant depression (TRD). The research will be conducted through June 30, 2029, and focuses on developing personalized medicine approaches...
- Grant Award Summary The National Institute of Mental Health (NIMH) awarded Stony Brook University a $437,125 Project Grant under the Mental Health Research Grants program (CFDA 93.242) for the period July 1, 2026, through June 30, 2028. This proof-of-concept research initiative will investigate the biological mechanisms underlying repetitive transcranial magnetic stimulation (rTMS) efficacy in treating major depressive disorder (MDD). The study will enroll 10 treatment-seeking MDD participants...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $100,228 under the Mental Health Research Grants program (CFDA 93.242) to investigate the role of ketamine in modulating intrinsic neural timescales in treatment-resistant depression (TRD). The award, dated November 26, 2026, with a completion date of June 30, 2029, supports basic and clinical research examining how ketamine normalizes...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded The Leland Stanford Junior University a Project Grant of $192,192 under the Mental Health Research Grants program (CFDA 93.242) on April 15, 2026, with a completion date of March 31, 2031. This award supports the development of an artificial intelligence foundation model for functional neuroimaging to advance personalized treatment prediction, treatment stratification, and biotype discovery in Major Depressive...
PRECISION FUNCTIONAL MAPPING IN TREATMENT-RESISTANT DEPRESSION - TREATMENT-RESISTANT DEPRESSION (TRD), DEFINED AS REPEATED FAILURE TO RESPOND TO TREATMENT, IS THE MOST VIRULENT FORM OF MAJOR DEPRESSIVE DISORDER (MDD), AND CLAIMS A DISPROPORTIONATE FRACTION OF MORBIDITY AND MORTALITY. THE OVERWHELMING COSTS OF DEPRESSION HAVE MOTIVATED A DECADES-LONG SEARCH FOR MEANINGFUL BIOMARKERS. HOWEVER, DESPITE SUBSTANTIAL EFFORT, AND THE PROMISE OF FUNCTIONAL BRAIN IMAGING AS A NON-INVASIVE TOOL FOR WHOLE-BRAIN MEASUREMENTS, THE IDENTIFICATION OF BIOMARKERS OF DEPRESSION FOR READY CLINICAL USE HAS REMAINED ELUSIVE. THE MAJOR IMPEDIMENTS TO PROGRESS INCLUDE SUBSTANTIAL PHENOTYPIC HETEROGENEITY IN TYPICAL MDD COHORTS AND UNRELIABLE AND IMPRECISE IMAGING MEASURES. DURING HIS GRADUATE AND RESIDENCY YEARS, THE PRINCIPAL INVESTIGATOR OF THIS PROPOSAL DEVELOPED NOVEL METHODS FOR PRECISE FUNCTIONAL NEUROIMAGING, KNOWN AS `PRECISION FUNCTIONAL MAPPING' (PFM), WHICH HAVE BEEN PREVIOUSLY APPLIED TO STUDY BRAIN ORGANIZATION IN HEALTHY INDIVIDUALS. THE PRESENT K99/R00 PATHWAY TO INDEPENDENCE AWARD PROPOSAL IS DESIGNED TO APPLY THESE NEW METHODS TO ADDRESS THESE PREVIOUS LIMITATIONS AND IDENTIFY TRAIT AND STATE BIOMARKERS OF PATHOLOGY IN TRD. IN ORDER TO ACHIEVE THESE GOALS, A COMPREHENSIVE CAREER DEVELOPMENT AGENDA HAS BEEN STRUCTURED TO TRAIN THE PI IN THE EVALUATION AND MANAGEMENT OF THIS SEVERELY ILL POPULATION. THE PI WILL ALSO LEARN HOW TO IMPLEMENT ECOLOGICALLY VALID TOOLS FOR PRECISE BEHAVIORAL AND PSYCHIATRIC ASSESSMENTS. THESE TRAINING AIMS WILL BE PURSUED WITH THE GUIDANCE AND MENTORSHIP OF DRS. CHARLES CONWAY, DEANNA BARCH, ERIC LENZE, NICO DOSENBACH, AND ABRAHAM SNYDER, WORLD EXPERTS IN PSYCHIATRIC ASSESSMENT, DIMENSIONS OF PSYCHOPATHOLOGY, HUMAN SUBJECTS STUDY DESIGN, ECOLOGICAL MOMENTARY ASSESSMENT (EMA), COGNITIVE NEUROSCIENCE, AND FUNCTIONAL NEUROIMAGING METHODS. DURING THE TRAINING K PHASE, THE PI WILL ACQUIRE A PROOF-OF-PRINCIPLE DATASET OF EXTENDED AND REPEATED RESTING FMRI DATA ON WELL-CHARACTERIZED TRD PATIENTS, TREATMENT-RESPONSIVE MDD PATIENTS, AND HEALTHY CONTROLS, IN ORDER TO OPTIMIZE THE QUANTITATIVE REPRODUCIBILITY OF SINGLE-SUBJECT FUNCTIONAL NETWORK MAPS DERIVED FROM RESTING STATE FUNCTIONAL CONNECTIVITY (RSFC; AIM 1). IN THE R00 PHASE OF THE AWARD, A LARGE COHORT (N=90) OF TRD, TREATMENT-RESPONSIVE MDD AND HEALTHY CONTROLS WILL BE EVALUATED TO IDENTIFY BRAIN IMAGING TRAIT BIOMARKERS OF TREATMENT-RESISTANT DEPRESSION (AIM 2). TO SEPARATE STATE FROM TRAIT BIOMARKERS, DENSE TIME COURSES OF IMAGING DATA, AS WELL AS EMA, WILL BE ACQUIRED ON TRD PATIENTS WHILE THEY UNDERGO ELECTROCONVULSIVE THERAPY (ECT) TREATMENT (AIM 3). TOGETHER, THESE STUDIES ARE LIKELY TO REVEAL UNDERLYING NETWORK FEATURES OF DISEASE AND WILL DETERMINE WHETHER RSFC CAN BE RELIABLY USED AS A BIOMARKER FOR TRD. THE TOOLS AND APPROACH LAID OUT IN THIS PROPOSAL WILL NATURALLY EXTEND TO EVALUATIONS OF OTHER TREATMENT MODALITIES AND NEUROPSYCHIATRIC DISORDERS. WITH THE SKILLS AND EXPERTISE GAINED THROUGH THIS TRAINING AND RESEARCH PROGRAM, THE PI WILL BE WELL-POSITIONED TO PURSUE AN INDEPENDENT CAREER AS A PHYSICIAN SCIENTIST.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $249.0k | 6/24/25 | ||
| Not listed | $0 | 10/22/24 | ||
| Not listed | $0 | 10/22/24 | ||
| Not listed | $0 | 9/26/24 | ||
| Not listed | $0 | 9/26/24 |